- Home
- CRVS vs NCV Comparison
CRVS vs NCV Comparison
Compare CRVS & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NCV
- Stock Information
- Founded
- CRVS 2014
- NCV 2003
- Country
- CRVS United States
- NCV United States
- Employees
- CRVS N/A
- NCV N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- CRVS Health Care
- NCV Finance
- Exchange
- CRVS Nasdaq
- NCV Nasdaq
- Market Cap
- CRVS 257.0M
- NCV 299.1M
- IPO Year
- CRVS 2016
- NCV N/A
- Fundamental
- Price
- CRVS $3.21
- NCV $13.06
- Analyst Decision
- CRVS Strong Buy
- NCV
- Analyst Count
- CRVS 5
- NCV 0
- Target Price
- CRVS $12.63
- NCV N/A
- AVG Volume (30 Days)
- CRVS 704.3K
- NCV 405.1K
- Earning Date
- CRVS 05-05-2025
- NCV 01-01-0001
- Dividend Yield
- CRVS N/A
- NCV 12.48%
- EPS Growth
- CRVS N/A
- NCV N/A
- EPS
- CRVS N/A
- NCV N/A
- Revenue
- CRVS N/A
- NCV N/A
- Revenue This Year
- CRVS N/A
- NCV N/A
- Revenue Next Year
- CRVS N/A
- NCV N/A
- P/E Ratio
- CRVS N/A
- NCV N/A
- Revenue Growth
- CRVS N/A
- NCV N/A
- 52 Week Low
- CRVS $1.30
- NCV $2.84
- 52 Week High
- CRVS $10.00
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- NCV 41.29
- Support Level
- CRVS $3.06
- NCV $12.77
- Resistance Level
- CRVS $3.45
- NCV $13.40
- Average True Range (ATR)
- CRVS 0.37
- NCV 0.19
- MACD
- CRVS -0.10
- NCV 0.02
- Stochastic Oscillator
- CRVS 8.77
- NCV 46.16
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.